SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes.

Pradip MukhopadhyayDebmalya SanyalPurushottam ChatterjeeKaushik PanditSujoy Ghosh

Published in: The Journal of clinical endocrinology and metabolism (2023)

SGLT2i reduce MACE without any discernable significant reduction of in the incidence of MI or Stroke (fatal and non-fatal), probably implicating mechanisms unrelated to anti-atherogenic effects.

Keyphrases

type diabetes
atrial fibrillation
heart failure
risk factors
left ventricular
glycemic control
metabolic syndrome
cord blood
blood brain barrier